Paclitaxel and carboplatin are standard anticancer drugs used to treat ovarian, primary peritoneal, and fallopian tube cancers. In this study, researchers want to see if adding an investigational drug called AMG 386 to this therapy is more effective than the standard treatment alone. AMG 386 works by inhibiting the development of the blood vessels that tumors need to grow and spread.
In this study, patients with stage III or IV ovarian, primary peritoneal, and fallopian tube cancers will be randomly assigned to receive one of two regimens of therapy: paclitaxel/carboplatin with AMG 386 followed by weekly AMG 386 for 18 months, or paclitaxel/carboplatin with a placebo followed by weekly placebo for 18 months. All medications given in this study are administered intravenously (by vein).